The percentage of American adults who are currently taking a GLP-1 drug for weight loss is 11%, according to a new survey from Gallup. That’s up from 8% in 2025 and 3% in 2024, according to the polling firm. Gallup surveyed 5,065 U.S. adults from May 28 to June 5, 2026 and first asked respondents whether they’ve ever taken weight loss medications like semaglutide (sold under brand names like Ozempic and Wegovy), liraglutide (prescribed under the name Saxenda) or tirzepatide (brand names Mounjaro and Zepbound). The percentage of Americans who have ever tried these medications is currently 15%, according to Gallup, up from 12% in 2025 and 6% in 2024. The percentage of Americans who have heard of these drugs for weight loss has also reached an all-time high (91%), up from 80% in 2024. The U.S. FDA approved the use of Wegovy for weight loss in 2021 and Zepbound in late 2023, kicking off mainstream use of the products among Americans. Wegovy is made by Novo Nordisk and Zepbound is made by Eli Lilly.
Gallup notes that obesity reached a record high in the U.S. in 2022 at 39.9% but has ticked down to 36.4%, according to the latest data based on self-reported height and weight. That dip has been credited to the large number of Americans now using GLP-1 drugs.
